Skip to main content

Table 1 Exclusion ciriteria

From: Pre-Study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis

Previous ERCP

Known allergy or intolerance to one of the compounds used in the study

Participation in another interventional trial during the previous four weeks

Pregnancy and breast feeding

current acute pancreatitis

Renal insufficiency ≥ stage 4 (K/DOQI), i.e. MDRD-GFR < 30 ml/min/1,73 m2)

Hyperthyroidism

Symptomatic bradycardia <35 bpm

Atrioventricular block > 1° or other cardial conduction defects

Myasthenia gravis

Liver cirrhosis Child C

Overt coagulopathy

Kidney stone diathesis (calcium-magnesium-ammonium-phosphate stones)

Mental impairment, addiction or other disorders leading to the patients inability to understand the scope and possible consequences of a participation in a clinical trial

Magnesium medication within 14 days before the procedure

Inability to give informed consent